S100A12 as blood biomarker for non-invasive diagnosis of endometriosis

The present invention relates to a method of assessing whether a patient has or is at risk of developing endometriosis by determining the amount or concentration of S100A12 in a sample of the patient and comparing the determined amount or concentration to a reference, a method of selecting a patient for therapy, and methods of monitoring a patient who has endometriosis or is being treated against endometriosis. 本发明涉及通过确定患者的样品中的S100A12的量或浓度以及将所确定的量或浓度与参考进行比较来评定患者是否患有子宫内膜异位症或具有发展子宫内膜异位症的风险的方法，选择供进行疗法的患者的方法，以及监测患有子宫内膜异位症或正在针对子宫内膜异位症进行治疗的患者的方法。